307520-98-5

Upstream product

• 883242-48-6 1-(3,4-bis-benzyloxy-phenyl)-3-(2,4-dihydroxy-phenyl)-propane-1,3-dione 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 174398-83-5 ethyl 3,4-bis(benzyloxy)benzoate 
• 307521-38-6 3-(3-chloropropoxy)-3',4'-dibenzyloxyflavone 
• 3943-89-3 Ethyl protocatechuate 
• 100-39-0 benzyl bromide 

Downstream Products

• 307521-07-9 3',4'-dibenzyloxy-7-(hydroxyethoxy)flavone 
• 307521-34-2 7-(3-chloropropoxy)-3',4'-dibenzyloxyflavone 
• 2150-11-0 3',4',7-trihydroxyflavone 
• 883242-55-5 3',4'-dibenzyloxy-7-(2,3-epoxypropoxy)flavone 
• 883242-80-6 7-(2-bromo-ethoxy)-3',4'-dibenzyloxy-flavone 
• 307521-10-4 3',4'-dibenzyloxy-7-(3-dimethylaminopropoxy)flavone 
• 30797-60-5 3’,4’-dihydroxy-7-methoxyisoflavone 
• 307521-05-7 3',4'-dibenzyloxy-7-methoxyflavone 

Relevant academic research and scientific papers

Natural product-based design, synthesis and biological evaluation of 2′,3,4,4′-tetrahydrochalcone analogues as antivitiligo agents

A bioactive component, 2′,3,4,4′-tetrahydrochalcone (RY3-a) was first isolated from Vernohia anthelmintica (L.) willd seeds, and a set of its analogs, RY3-a-1–RY3-a-15 and RY3-c were designed and synthesized. Biological activity assays showed that RY3-c exhibited better melanogenesis and antioxidant activity and lower toxicity in comparison with RY3-a and butin. Further study tests showed that RY3-c exhibited better melanogenesis activity compared with the positive control 8-methoxypsoralan (8-MOP) in a vitiligo mouse model, suggesting that RY3-c is a good candidate antivitiligo agent. Mechanistic studies showed that RY3-c could repair cell damage induced by excessive oxidative stress and may exert melanin synthesis activity in the mouse melanoma B16F10 cell line by activating the mitogen-activated protein kinase (MAPK) pathway and the upregulation of c-kit.

Flavone-based novel antidiabetic and antidyslipidemic agents

The hybrid congeners 62-90 of 6- and 7-hydroxyflavones with aminopropanol have been synthesized and evaluated for their antidiabetic activity in sucrose-challenged low-dosed streptozotocin (STZ)-induced diabetic rats and db/db mice. The optical enantiomers 70a, 70b, 90a, and 90b of two congeners 70 and 90 exhibiting consistent antidiabetic and antidyslipidemic activities were also prepared, and their antidiabetic activity results indicate its association mainly with S isomers. These compounds also lower cholesterol and TG profiles while improving high-density lipoprotein cholesterol to CHOL ratio in db/db mice. The bioavailability of compound 70 and its isomer varies between 27 and 29% whereas that of the more polar compound 90a is poor as determined in rat by oral and intraperitoneal administrations. Published 2012 by the American Chemical Society.

OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS

The present invention provides novel substituted flavone derivatives which exhibit anti- hyperglycemic and antidyslipedemic activity. The invention also provides a method for controlling type ii diabetes and associated hyperlipidemic conditions in a mammal by administering compound of the present invention and compositions containing these derivatives.

SMALL MOLECULE ANTAGONISTS OF XIAP FAMILY PROTEINS

The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of XIAP family proteins. In particular, the present invention provides embelin and other XIAP inhibitors and methods of using these compounds as ant

Novel flavonoids

Novel flavonoids of formula (I) 1where A and E form together a C—C or C=C bond; R1, R2, R3, and R4 are H, OH, O(CH2)n— aromatic group, n=0-8; O(CH2)n N(CH3)q with n=0-8, q=0-3; O(CH2)n OH with n=1-8; O(CH2)n-halide with n=1-8; O(CH2)n COOH with n=0-8; O(CH2)n COOR′ with n=0-8 and R′ is C1-C8 alkyl or an aromatic group; O(CH2)n CONH R″ with n=0-8 and R″ is C1-C8 alkyl or an aromatic group, and sugars in mono-, di- or trimeric form or analogues thereof, with the proviso that R1 is not H, at least two of R2, R3 and R4 are H, and at most one of R1, R2, R3 and R4 is OH, are useful for the treatment of drug-induced toxicity, doxorubicin-induced cardiotoxicity, free radical mediated diseases, lung diseases, cancer, diabetes mellitus, cardiovascular disease, or arteriosclerosis.

Synthesis of novel 3,7-substituted-2-(3',4'-dihydroxyphenyl)flavones with improved antioxidant activity

A series of 3,7-disubstituted-2-(3',4'-dihydroxyphenyl)flavones was synthesized as potential cardioprotective agents in doxorubicin antitumor therapy. The influence of substituents on the 3 and 7 positions of the flavone nucleus on radical scavenging and